Le Lézard
Classified in: Health
Subjects: CPN, POL, AVO

Dr. Oz Pledges To Support U.S. Term Limits Amendment In Senate


WASHINGTON, Jan. 20, 2022 /PRNewswire/ -- U.S. Term Limits (USTL), the leader in the non-partisan national movement to limit terms for elected officials, announces that Dr. Mehmet Oz, 2022 United States Senate candidate in Pennsylvania has signed the U.S. Term Limits pledge. With his pledge, Dr. Oz promises if elected to support the U.S. Term Limits amendment of three (3) House terms and two (2) Senate terms and no longer limit. Pennsylvanians regardless of political affiliation overwhelming support term limits for Congress.

The U.S. Term Limits amendment pledge is provided to every announced candidate for federal office. The U.S. Term Limits constitutional amendment has been introduced in both the U.S. Senate by Senator Ted Cruz and his colleagues (SJR 3) and the U.S. House by Representative Ralph Norman (HJR 12).

"Our Founding Fathers did not want people to make careers out of government," said Dr. Mehmet Oz. "When a treatment just isn't working in medicine, we make changes and try a different solution. That's why I support term limits." 

"Dr. Oz is a name known throughout not just Pennsylvania but the nation for his television show and I am thrilled that he has signed the pledge supporting term limits on Congress is on the U.S. Term Limits team," said Joh Eichelberger, Pennsylvania State Co-Chair for U.S. Term Limits.

"We are gaining momentum throughout Pennsylvania for congressional term limits as seen by Dr. Oz's pledge so that we can join the growing number of states supporting congressional term limits," said Andrew Dinniman, Pennsylvania State Co-Chair for U.S. Term Limits.

Phillip Blumel, President of U.S. Term Limits noted, "We have seen a dramatic increase in supporters wanting term limits on Congress. More than 82% of Americans have rejected the career politician model and want to replace it with citizen leadership. The way to achieve that goal is through congressional term limits."

According to the latest nationwide poll on term limits conducted by Scott Rasmussen term limits enjoy wide bipartisan support. Rasmussen's analysis states, "Support for term limits is broad and strong across all political, geographic and demographic groups. An overwhelming 82% of voters approve of a constitutional amendment that will place term limits on members of Congress."

Media Contact: David Johnson, Strategic Vision PR Group
Ph: (404) 380-1079
Email: [email protected]

SOURCE U.S. Term Limits


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: